Ralph Levitt

4.7k total citations
67 papers, 3.6k citations indexed

About

Ralph Levitt is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Ralph Levitt has authored 67 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 14 papers in Genetics. Recurrent topics in Ralph Levitt's work include Cancer Treatment and Pharmacology (12 papers), Glioma Diagnosis and Treatment (8 papers) and HER2/EGFR in Cancer Research (8 papers). Ralph Levitt is often cited by papers focused on Cancer Treatment and Pharmacology (12 papers), Glioma Diagnosis and Treatment (8 papers) and HER2/EGFR in Cancer Research (8 papers). Ralph Levitt collaborates with scholars based in United States, India and Canada. Ralph Levitt's co-authors include James E. Krook, Loren K. Tschetter, J A Mailliard, James B. Gerstner, Jeff A. Sloan, Steven R. Alberts, Harry S. Wieand, Carl G. Kardinal, Richard M. Goldberg and Kendrith M. Rowland and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer.

In The Last Decade

Ralph Levitt

67 papers receiving 3.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ralph Levitt United States 27 2.1k 892 682 670 523 67 3.6k
Gary Richardson Australia 19 2.6k 1.3× 1.2k 1.4× 478 0.7× 734 1.1× 219 0.4× 110 3.8k
Shenhong Wu United States 35 2.9k 1.4× 1.7k 1.9× 424 0.6× 1.4k 2.2× 441 0.8× 96 5.5k
Cristine Allmer United States 23 1.4k 0.7× 599 0.7× 693 1.0× 757 1.1× 482 0.9× 84 2.9k
Abdel Hmissi Switzerland 17 2.7k 1.3× 900 1.0× 901 1.3× 549 0.8× 488 0.9× 34 4.1k
Francesco Di Costanzo Italy 32 3.5k 1.7× 2.4k 2.7× 693 1.0× 715 1.1× 228 0.4× 167 5.0k
G. Ganem France 27 3.3k 1.6× 1.1k 1.3× 842 1.2× 473 0.7× 189 0.4× 68 4.5k
Linda H. Colangelo United States 23 3.7k 1.8× 809 0.9× 1.5k 2.2× 446 0.7× 594 1.1× 44 4.8k
Mary Cabiddu Italy 34 2.5k 1.2× 1.3k 1.5× 887 1.3× 649 1.0× 192 0.4× 78 3.9k
Karen Borgonovo Italy 33 2.7k 1.3× 1.5k 1.7× 667 1.0× 545 0.8× 223 0.4× 83 3.8k
Muhammad Wasif Saif United States 25 1.7k 0.8× 639 0.7× 475 0.7× 562 0.8× 122 0.2× 129 2.7k

Countries citing papers authored by Ralph Levitt

Since Specialization
Citations

This map shows the geographic impact of Ralph Levitt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ralph Levitt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ralph Levitt more than expected).

Fields of papers citing papers by Ralph Levitt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ralph Levitt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ralph Levitt. The network helps show where Ralph Levitt may publish in the future.

Co-authorship network of co-authors of Ralph Levitt

This figure shows the co-authorship network connecting the top 25 collaborators of Ralph Levitt. A scholar is included among the top collaborators of Ralph Levitt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ralph Levitt. Ralph Levitt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Levitt, Ralph, et al.. (2013). Controversies in the management of brain metastases. Surgical Neurology International. 4(5). 231–231. 6 indexed citations
2.
Loprinzi, Charles L., Ernie Balcueva, Heshan Liu, et al.. (2011). A Phase III Randomized, Double-Blind, Placebo-Controlled Study of Pilocarpine for Vaginal Dryness: North Central Cancer Treatment Group Study N04CA. PubMed. 9(3). 105–112. 9 indexed citations
3.
Loprinzi, Charles L., Ralph Levitt, Debra L. Barton, et al.. (2006). Phase III Comparison of Depomedroxyprogesterone Acetate to Venlafaxine for Managing Hot Flashes: North Central Cancer Treatment Group Trial N99C7. Journal of Clinical Oncology. 24(9). 1409–1414. 86 indexed citations
4.
Loprinzi, Charles L., Ralph Levitt, Jeff A. Sloan, et al.. (2005). Medroxyprogesterone acetate (MPA) versus venlafaxine for hot flashes: A North Central Cancer Treatment Group trial. Journal of Clinical Oncology. 23(16_suppl). 8014–8014. 3 indexed citations
5.
Potti, Anil, Scott E. Forseen, Vijay Koka, et al.. (2004). Determination of HER-2/Neu Overexpression and Clinical Predictors of Survival in a Cohort of 347 Patients with Primary Malignant Brain Tumors. Cancer Investigation. 22(4). 537–544. 30 indexed citations
6.
Koka, Vijay, et al.. (2003). . American Journal of Clinical Oncology. 26(4). 332–335. 4 indexed citations
7.
Ganti, Apar Kishor, et al.. (2003). HER-2/neu Overexpression detected by Immunohistochemistry in Soft Tissue Sarcomas. American Journal of Clinical Oncology. 26(2). 188–191. 12 indexed citations
8.
9.
10.
Koch, Michael, et al.. (2002). Role of immunohistochemical identification of Her-2/neu and detection of variability in overexpression in pancreatic carcinoma.. PubMed. 22(3). 1593–7. 22 indexed citations
11.
Potti, Anil, et al.. (2002). Identification and relationship of HER-2/neu overexpression to short-term mortality in primary malignant brain tumors.. PubMed. 22(3). 1599–602. 18 indexed citations
12.
Marschke, Robert F., Joseph P. Grill, Jeff A. Sloan, et al.. (1999). Phase II Study of High-Dose Somatostatin Analogue in Patients Either Previously Treated or Untreated Who Have Extensive-Stage Small Cell Lung Cancer. American Journal of Clinical Oncology. 22(1). 15–17. 18 indexed citations
13.
Perry, Arie, Robert B. Jenkins, Judith R. OʼFallon, et al.. (1999). Clinicopathologic study of 85 similarly treated patients with anaplastic astrocytic tumors. Cancer. 86(4). 672–683. 49 indexed citations
14.
Tefferi, Ayalew, Ralph Levitt, Chin‐Yang Li, et al.. (1999). Phase II Study of 2-Chlorodeoxyadenosine in Combination With Chlorambucil in Previously Untreated B-Cell Chronic Lymphocytic Leukemia. American Journal of Clinical Oncology. 22(5). 509–509. 11 indexed citations
15.
Veeder, M H, et al.. (1996). Phase II study of 5-fluorouracil and leucovorin in recurrent primary brain tumor. Journal of Neuro-Oncology. 30(3). 243–6. 10 indexed citations
16.
Jett, James R., Andrew W. Maksymiuk, John Q. Su, et al.. (1994). Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer.. Journal of Clinical Oncology. 12(11). 2321–2326. 95 indexed citations
17.
Ingle, James N., Harry J. Long, Donald I. Twito, et al.. (1991). Combination hormonal therapy with tamoxifen plus fluoxymesteroneversus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis. Cancer. 67(4). 886–891. 91 indexed citations
18.
Patel, Shreyaskumar, Larry K. Kvols, R. G. Hahn, et al.. (1990). A phase II randomized trial of megestrol acetate or dexamethasone in the treatment of hormonally refractory advanced carcinoma of the prostate. Cancer. 66(4). 655–658. 24 indexed citations
19.
Mailliard, James A., Louis Letendre, Robert J. Dalton, et al.. (1986). Phase I–II trial of VP‐16 in the treatment of acute nonlymphocytic leukemia and blast crisis of chronic granulocytic leukemia. Medical and Pediatric Oncology. 14(6). 306–309. 5 indexed citations
20.
Mr, Wick, et al.. (1980). Malignant histiocytosis as a terminal condition in chronic lymphocytic leukemia.. PubMed. 55(2). 108–12. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gary Richardson Breakdown of academic impact, for papers by Shenhong Wu Breakdown of academic impact, for papers by Cristine Allmer Breakdown of academic impact, for papers by Abdel Hmissi Breakdown of academic impact, for papers by Francesco Di Costanzo Breakdown of academic impact, for papers by G. Ganem Breakdown of academic impact, for papers by Linda H. Colangelo Breakdown of academic impact, for papers by Mary Cabiddu Breakdown of academic impact, for papers by Karen Borgonovo Breakdown of academic impact, for papers by Muhammad Wasif Saif
Rankless by CCL
2026